

AD_____

Award Number: W81XWH-05-1-0546

TITLE: Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer

PRINCIPAL INVESTIGATOR: Rahul Ray, Ph.D.

CONTRACTING ORGANIZATION: Boston University
Boston, Massachusetts 02215-1301

REPORT DATE: October 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-10-2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 30 Sep 2005 – 29 Sep 2006	
4. TITLE AND SUBTITLE Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0546	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Rahul Ray, Ph.D. E-Mail: bapi@bu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Boston University Boston, Massachusetts 02215-1301				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The most significant achievement of this period is the development of a synthetic scheme to produce substantial quantity of our target compound i.e. 1,25-dihydroxyvitamin D3-3-bromoacetate. This is extremely important for the current project and for the future development of this compound for prostate cancer. We have also screened this compound against prostate and kidney cancer cells for its antiproliferative activity. In addition we have developed a mouse xenograft model to test the efficacy of this compound in reducing androgen-sensitive and androgen-insensitive prostate tumors in future studies.					
15. SUBJECT TERMS prostate cancer, vitamin D derivatives, animal models					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	28	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusions.....	10
References.....	
Appendices.....	11


Introduction

Therapeutic potential of 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) in prostate cancer is well-recognized. However, its clinical use has been restricted by its inherent calcemic toxicity. In recent studies we demonstrated that 1 α ,25-dihydroxyvitamin D₃-3-bromoacetate [1,25(OH)₂D₃-3-BE], a derivative of 1,25(OH)₂D₃ that covalently links 1,25(OH)₂D₃ inside the ligand-binding pocket of nuclear vitamin D receptor (VDR) is a strong antiproliferative and pro-apoptotic agent in several androgen-sensitive and androgen-refractory human prostate cancer cells. Furthermore, 1,25(OH)₂D₃-3-BE demonstrated strong anti-prostate tumor effect in athymic mice without toxicity. The goal of this project is to evaluate the translational potential of 1,25(OH)₂D₃-3-BE as a therapeutic agent for prostate cancer. This will be achieved by determining the efficacy of 1,25(OH)₂D₃-3-BE in mouse models of human androgen-sensitive and androgen-insensitive prostate cancer, as well as evaluating its molecular mechanisms of action in several *in vitro* studies.

Studies completed/goals achieved during the one year period (Year 1) of the project

Synthesis of 1,25(OH)₂D₃-3-BE

Success of all the studies included in this project are critically dependent on the availability of 1,25(OH)₂D₃-3-BE in substantial (milligram) quantities. In the past we synthesized this compound in a multi-step scheme using 1,25-dihydroxy-7-dehydrocholesterol as the starting material as shown in **Figure 1** (R. Ray, S.A. Holick, and M.F. Holick. Synthesis of a photoaffinity-labelled analog of 1,25-dihydroxyvitamin D₃. *Journal of the Chemical Society*,



Chemical Communications 11: 702-703 (1985). However, this starting material is no longer available. Therefore, we had to devise a synthetic scheme for obtaining substantial quantity of 1,25(OH)₂D₃-3-BE required for our studies by a scheme shown in **Figure 2**.




Figure 2: The new scheme for the synthesis of 1,25(OH)₂D₃-3-BE

Synthetic procedures:

- 3-TBDMS ether of 25-hydroxyvitamin D₃-SO₂ adduct (B):** Approximately 10 ml of SO₂ was condensed (-78⁰C) in a flask containing 200 mg of 25-hydroxyvitamin D₃ in a flask fitted with a trap that was cooled with dry ice-acetone (-78⁰C). The yellow solution was refluxed with stirring for 4 hours followed by removal of SO₂ with a stream of nitrogen to produce a foamy solid. The foam was dissolved in 5 ml of anhydrous DMF (distilled fresh from CaO) and TBDMSCl (1.5 X), imidazole (2 X) were added and the solution was stirred at 25⁰C for 20 hours followed by removal of DMF under vacuo, re-dissolving the residue in EtOAc. The organic solution was washed with water, organic layer was dried over anhydrous MgSO₄, and the solution was concentrated under vacuo. The residue was moved on to the next step without further purification.
- Trans-25-hydroxyvitamin D₃-3-TBDMS ether (C):** The crude from the previous step was dissolved in 95% EtOH (10 ml) and NaHCO₃ (244 mg) was added. The mixture was refluxed under argon for 90 min followed by addition of brine and extraction of the aqueous solution with EtOAc. The crude reaction product was purified by preparative TLC (silica plates, 1000μ, Analtech) to produce 56.7% of the desired product (C).
- Trans-1α,25-dihydroxyvitamin D₃-3-TBDMS ether (D):** A mixture of (C) (760 mg) and SeO₂ (192 mg) in 15 ml of anhydrous CH₂Cl₂ was refluxed under argon for 30 min followed by cooling to room temperature and addition of a solution of N-methylmorpholine-N-oxide (850 mg) in 15 ml of anhydrous CH₂Cl₂. The mixture was refluxed for an additional 60 min when TLC indicated almost complete reaction, and refluxing was stopped. The mixture was filtered and concentrated under vacuo. The crude reaction product was purified by preparative TLC to produce almost a quantitative amount of the desired product (D).

d. 1 α ,25-Dihydroxyvitamin D₃-3-TBDMS ether (E): 80 mg of (D), anthracene (10 mg), Et₃N (40 μ l) in 10 ml of toluene (in a quartz test tube) was irradiated from a Hanovia medium pressure mercury arc lamp for 75 min. The irradiated solution was concentrated and the crude mixture was purified by preparative TLC (1000 μ plate, 4:1 EtOAc-hexanes, multiple elutions, the desired product (most polar of all the photo-products) was isolated as a gummy liquid in 67% yield.

e. 1 α ,25-Di-tetrahydropyranyl, 3-TBDMS ether of 1 α ,25-dihydroxyvitamin D₃ (F): A solution of (E) (35 mg), DHP (60 μ l) and a few crystal of PPTS in 1.0 ml of anhydrous CH₂Cl₂ was stirred for two days followed by preparative TLC procedure to produce 34 mg (74%) of the desired product (F).

f. 1 α ,25-Di-tetrahydropyranyl,1 α ,25-dihydroxyvitamin D₃ (G): A solution of (F) (17 mg) and 20 μ l of TBAF (1M in THF) was dissolved in anhydrous THF (1 ml) and stirred for 20 hours. The reaction mixture was diluted with EtOAc, washed with brine, dried over anhydrous MgSO₄, concentrated and purified by preparative TLC to produce quantitative amount of (G).

g. 1 α ,25-Di-tetrahydropyranyl,1 α ,25-dihydroxyvitamin D₃-3-bromoacetate (H): A solution of (G) (8 mg), DCC (2.5 X, 8.12 mg), DMAP (catalytic), bromoacetic acid (1.5 X, 3.3 mg) in one ml of anhydrous CH₂Cl₂ was stirred for 20 hours followed by filtration of the mixture, concentration of the filtrate by a stream of nitrogen and preparative TLC purification of the reaction mixture produced quantitative amount of the desired product (H).

h. 1 α ,25-Dihydroxyvitamin D₃-3-bromoacetate: A solution of (H) (7 mg) was dissolved in 3 ml of AcOH-THF-H₂O (4:2:1) and heated at 50⁰C for 20 hours. Volatile matters were removed under a stream of nitrogen and the product was isolated by preparative TLC. Yield of the desired product 1 α ,25-dihydroxyvitamin D₃-3-bromoacetate was quantitative.

Notes:

1. All the intermediate products were physicochemically characterized by NMR.
2. Purity of the final product (1 α ,25-dihydroxyvitamin D₃-3-bromoacetate) was determined by HPLC (Altech 10 μ C₁₈ column, 5% H₂O-MeOH solvent, 0.5 ml/min, 254 nm detection).
3. NMR spectrum of the final product (1 α ,25-dihydroxyvitamin D₃-3-bromoacetate) is included in Figure 3.




Figure 3: NMR spectrum of the the new batch of 1,25(OH)₂D₃-3-BE

Comparison of the new batch of 1,25(OH)₂D₃-3-BE with the old batch

Since we synthesized our compound (1,25(OH)₂D₃-3-BE) by a different synthetic scheme (Figure 1 vs. Figure 2) we were compelled to compare the in vitro cellular activity of the same compound obtained from different synthetic schemes.

Determination of the antiproliferative activity of 1,25(OH)₂D₃-3-BE (new compound and old compound) in Caki-1 kidney cancer cells by ³H-thymidine incorporation assay

Procedure: Caki-1 cells (ATCC, Manassas, VA) were grown in McCoy's 5A media with 5% fetal bovine serum (FBS) according to manufacturer's specifications and then plated onto 24-well plates and grown to approximately 60% in the same media containing 5% FBS followed by overnight serum-starvation and treatment with 10⁻⁶⁻⁷ M of 1,25(OH)₂D₃-3-BE (old or new batch) or 1,25(OH)₂D₃ or ethanol (control). Compounds were dissolved in minimum amount of ethanol and required aliquots of the ethanolic solutions of the compounds were added to McCoy's 5A media with 5% FBS. Volume of ethanol was adjusted so that its concentration was 0.1% v/v in the media.

³H-thymidine-incorporation assay: After the treatment media was removed from the wells and replaced with media containing ³H-thymidine (0.1 μCi) per well, and the cells were incubated for 3 hours at 37°C. After this period media was removed by aspiration and the cells were washed thoroughly (3 X 0.5 ml) with PBS. Then ice-cold 5% perchloric acid solution (0.5 ml) was added to each well and the cells were incubated on ice for 20 minutes. After this incubation, perchloric acid was removed by aspiration, replaced with 0.5 ml of fresh perchloric

acid solution and the cells were incubated at 70°C for 20 minutes. Solution from each well was mixed with scintillation fluid and counted in a liquid scintillation counter. There were eight (8) wells per sample, and statistics were carried out by Student's t test. Results are expressed as




Figure 4: ³H-Thymidine incorporation assay of Caki-1 cells with 1,25(OH)₂D₃ and 1,25(OH)₂D₃-3-BE (New Batch)

percent incorporation of radioactivity versus ethanol-control.

Results: Results of this assay are shown in Figures 4 and 5. In this cell line 1,25(OH)₂D₃-3-BE was a much stronger antiproliferative agent than 1,25(OH)₂D₃ in both dose levels tested (10⁻⁶⁻⁷M); and both 'new' and 'old' batches of 1,25(OH)₂D₃-3-BE were same in terms of their




Figure 5: ³H-Thymidine incorporation assay of Caki-1 cells with 1,25(OH)₂D₃ and 1,25(OH)₂D₃-3-BE (Old Batch)

antiproliferative activity.

Determination of the antiproliferative activity of the 'new batch' of 1,25(OH)₂D₃-3-BE' in DU-145 human androgen-insensitive prostate cancer cells

DU-145 cells were grown in DMEM media containing 5% FBS and plated on to 24-well plates. The cells were grown to approximately 60% confluence and treated with 10⁻⁶⁻⁷M of 1,25(OH)₂D₃-3-BE (new batch) or 1,25(OH)₂D₃, followed by ³H-thymidine incorporation assay as described earlier.

Results: Results of this assay (not shown) demonstrated that the 'new batch' of 1,25(OH)₂D₃-3-BE' is strongly antiproliferative towards DU-145 prostate cancer cells.

Studies to develop a mouse xenograft model of androgen-insensitive human prostate tumor

Once our compound (1,25(OH)₂D₃-3-BE) became available in significant quantity we initiated a study to develop a model of androgen-insensitive human prostate tumor in a mouse xenograft model.

Procedure: Six (6) weeks old male athymic mice, weighing approximately 20 gm (Charles River) were kept on normal animal diet and water *ad libitum*. DU-145 human androgen insensitive prostate cancer cells were grown in DMEM media containing 5% FBS. When the cells grew to confluence they were trypsinized and centrifuged. The cell pellet was suspended in PBS. An aliquot was counted for cell-number. Approximately 10⁶ cells/ 100 µl of suspension was injected (with a 26 gauge needle) under the skin in the flank of the mice. Appearance of tumor was detected within four (4) days. Palpable tumor with an approximate size of 1 mm³ was obtained within two weeks post-injection.

Plans for the immediate future: As described above we have developed a mouse xenograft model of androgen-insensitive prostate tumor. Currently we are in the process of developing a study to determine maximum tolerated dose (MTD) of 1,25(OH)₂D₃-3-BE in a mouse model. Once that is established we will order a large number of athymic mice for our proposed efficacy study of 1,25(OH)₂D₃-3-BE.

During the past one year our efforts with 1,25(OH)₂D₃-3-BE and a related has generated three (3) abstracts and one manuscript that are included in the appendix.

KEY RESEARCH ACCOMPLISHMENTS

- Synthesized substantial quantity of 1,25(OH)₂D₃-3-BE by a new synthetic route (reportable separately in a synthetic/edicinal chemistry journal) that will be required for the *in vitro* and *in vivo* studies included in this project.
- Physicochemically determined the structural and chemical homogeneity of the compound (1,25(OH)₂D₃-3-BE).
- Compared the antiproliferative activity of the 'new batch' of 1,25(OH)₂D₃-3-BE with the 'old batch' in an antiproliferative assay in Caki-1 kidney cancer cell-line.

- Determined the antiproliferative activity of the ‘new batch’ of 1,25(OH)₂D₃-3-BE in DU-145 human androgen-insensitive prostate cancer cells.
- Established a mouse xenograft model androgen-insensitive prostate tumor model in our laboratory.
- Extended our anti-cancer studies of 1,25(OH)₂D₃-3-BE beyond prostate cancer to kidney cancer. This resulted in a manuscript (included in the appendix) that has been provisionally accepted for publication in *Molecular Cancer Therapeutics*.

REPORTABLE OUTCOME

During the past one year our efforts with 1,25(OH)₂D₃-3-BE and a related has generated three (3) abstracts and one manuscript that are included in the appendix.

CONCLUSION

Our effort for the past one year has established the groundwork for the current year and beyond to develop 1,25(OH)₂D₃-3-BE and related compounds for prostate and other cancers.

APPENDIX

Meeting Abstract 1:

Abstract:

Vitamin D and Cancer. Brown University Symposium on Vitamin D. Seekonk, MA, September, 2005

Abstract:

VDR-alkylating derivatives of vitamin D for potential cancer-therapy. Rahul Ray, Ph.D. Boston University School of Medicine, Boston, MA

Protein and DNA-alkylating agents are common in cancer therapy. But, majority of them are non target-specific causing systemic toxicity. We hypothesized that derivatives of 25-OH-D₃ and 1,25(OH)₂D₃ that covalently attach to the ligand binding pocket of VDR in the target cells might reduce the catabolic process, lower the therapeutic dose and diminish toxicity. Recently we observed that bromoacetate derivatives of 25-OH-D₃ and 1,25(OH)₂D₃, that alkylate the ligand-binding site of VDR, produced significantly stronger antiproliferative effect than the hormone in several cancer cells. The effect was particularly strong in a host of androgen sensitive and androgen insensitive prostate cancer cells, as well as kidney and bladder cancer cells. The reason for this cancer-specific effect is unknown at this point. In vivo studies in nude mice, bearing DU-145 inoculated prostate tumor demonstrated strong anti-tumor activity of the abovementioned compounds without toxicity. In conclusion, VDR-alkylation is a potentially important method for developing vitamin D-based therapeutic agents for cancer.

Meeting Abstract 2:

Endocrine Society National Meeting, Boston, MA, June 2006

Abstract:

A vitamin D receptor-alkylating derivative of 1,25-dihydroxyvitamin D₃ induces apoptosis in prostate and kidney cancer cells and displays anti-tumor effect in a DU-145 mouse xenograft model. Rahul Ray, James M. Lambert, Sibaji Sarkar and Kelly S. Persons. Boston University School of Medicine, Boston, MA, and University of Colorado Health Sciences Center, Aurora, CO.

Currently no therapy is available for prostate cancers that fail to respond to androgen therapy. Most human prostate cancer cells contain the receptor for 1 α ,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃); and numerous studies have shown that prostate cancer cells respond to 1,25(OH)₂D₃ by enhancing differentiation and decreasing proliferation. Furthermore, several epidemiological studies have suggested a strong connection between prostate cancer mortality and exposure to sunlight, which is required for the production of vitamin D in the body. These findings strongly support the use of vitamin D-based agents in prostate cancer. However,

inherent toxicity of 1,25(OH)₂D₃ in therapeutic doses has limited its use and spurred a strong interest in developing less toxic analogs of 1,25(OH)₂D₃ for cancer-therapy.

In recent studies we demonstrated that 1 α ,25-dihydroxyvitamin D₃-3-bromoacetate (1,25(OH)₂D₃-3-BE), a derivative of 1,25(OH)₂D₃ that covalently links 1,25(OH)₂D₃ inside the ligand-binding pocket of nuclear vitamin D receptor (VDR) strongly inhibits the growth of LNCaP, PC-3, DU-145 and LAPC-4 prostate cancer cells and induces apoptosis as determined by FACS analysis. We also demonstrate that 1,25(OH)₂D₃-3-BE modulates the message for 1,25-dihydroxyvitamin D₃-24-hydroxylase, a key gene in the vitamin D pathway; and the signal is obliterated by ZK 159222, a VDR-antagonist. Furthermore, in a recent preliminary study we observed that 1,25(OH)₂D₃-3-BE produced strong anti-prostate tumor effect in DU-145 mouse xenograft model without toxicity.

In addition to prostate cancer cells we recently observed that 1,25(OH)₂D₃-3-BE strongly inhibits the growth and induces apoptosis in two human kidney cancer cell lines.

Protein and DNA alkylating agents are standard therapeutic agents for cancer. But, these drugs are non-specific and, produce significant to severe side effects, particularly at therapeutic doses. On the other hand, affinity alkylating derivatives of drugs and drug-candidates specifically alkylate the substrate/ligand-binding sites of target enzymes/receptors, thereby they can potentially modulate the biological property associated only with the target molecules; thereby lowering the required dose and toxicity. We hereby report that a derivative of 1,25(OH)₂D₃, that alkylates the hormone-binding pocket of VDR demonstrates a strong translational potential as non-toxic therapeutic agents for prostate and renal cancers.

Meeting Abstract 3:

International Conference on Biotechnology and nanotechnology. Kolkata, India, March, 2006

Abstract:

Nuclear transcriptional factors as molecular targets for drug-discovery and delivery: bench to bedside. Rahul Ray, Ph. D, Boston University School of Medicine, Boston, Massachusetts, USA

In the past discovery of drugs for various diseases used to be a 'hit or miss' process. It is no longer the case. Advancement of our knowledge regarding biology of diseases, and particularly of the intricate biochemical processes have given us appropriate means of carefully choosing the specific target for any particular disease. This has been aptly complemented by a plethora of highly efficient modern techniques, such as x-ray crystallography, nuclear magnetic resonance imaging, computer simulation, combinatorial chemistry, nanotechnology etc.

Research from our group has focused primarily on cancer drug-discovery and its delivery to the desired target. Despite a well-coordinated effort by scientists in the world over; and availability of a sea of knowledge, cancer in general has remained a scourge and a major killer. It is now realized that each malignancy is unique. In addition, our gender, socio-economic status, and life style have a profound effect on cancer development, growth and mortality.

In our effort we focused on two small naturally occurring molecules (vitamin D and estrogen) and their cognate transcriptional factors/nuclear hormone receptors, namely vitamin D receptor (VDR) and estrogen receptor (ER). Vitamin D is strongly implicated in many cancers, while estrogen is implicated in malignancies of breast, ovary and endometrium. On the other hand

VDR and ER are proteins that are abundant in the nucleus of the cancer cells; and act as highly efficient scavengers of vitamin D and estrogen. This binding/scavenging process is ultimately manifested in the biological properties of vitamin D and estrogen. In layman's terms a key fits perfectly in a unique key-hole to open the door to a room with hidden treasures. Allegorically key is the small molecule (vitamin D, estrogen), while the door is the hormone receptor (ER, VDR) and access to the hidden treasure is the property/manifestation of the property of the key

We developed a computer simulated model of the three-dimensional structure of VDR to design novel analogs of vitamin D (the key) that cross-links to the ligand-binding site (the key hole) of VDR (the door). We postulate that such a process might enhance the biological potency of the parent hormone. As support for this hypothesis we observed that these compounds strongly inhibit the growth of several cancer cells; and the effect is strongest in prostate, kidney and bladder cancer cells. Under treatment, these cancer cells undergo programmed cell-death (apoptosis) as evidenced by key signatures of cell-death including caspase-activation and DNA-fragmentation, demonstrating the potential of these vitamin D compounds to treat these cancers.

Specially bred rodents such as mouse and rat are commonly used animal models to test efficacy of an experimental drug. In other words human cancer cells, grown in petri dish, can be injected under the skin of these animals to grow tumors (xenograft model). Then the animals can be treated with an experimental drug to determine its efficacy in reducing/eliminating tumor. In essence these animals act as test tubes in a chemical/biochemical laboratory, except these animals represent a truly living system close to humans.

A vitamin D receptor-alkylating derivative of 1 α ,25-dihydroxyvitamin D₃ exerts antiproliferative and pro-apoptotic effects in human kidney cancer cells.

James R. Lambert², Sibaji Sarkar¹, Christian D. Young², Kelly S. Persons¹, Douglas V. Faller¹, Michael F. Holick¹, and Rahul Ray^{1,*}

¹Department of Medicine, Boston University School of Medicine, Boston, MA; ²Department of Pathology, University of Colorado Health Science Center, Aurora, CO

*Rahul Ray, Ph.D., Department of Medicine, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, telephone: 617-638-8199, FAX: 617-638-8194, e. mail: bapi@bu.edu

Short Title: An alkylating 1,25-dihydroxyvitamin D₃ derivative for renal cancer

Abstract

Renal cell carcinoma is a fatal disease with very few therapeutic options. 1 α ,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), the vitamin D hormone has shown strong promise as a general antiproliferative agent in several malignancies, yet its therapeutic application has been limited by its inherent toxicity, particularly at pharmacological dose. We have developed 1 α ,25-dihydroxyvitamin D₃-3-bromoacetate (1,25(OH)₂D₃-3-BE), a derivative of 1,25(OH)₂D₃ that covalently and specifically links to the hormone-binding pocket of vitamin D receptor (VDR) in target cells. We hypothesize that such a process might decrease/eliminate catabolic degradation, and enhance the efficacy of 1,25(OH)₂D₃-3-BE as an antiproliferative agent. In this communication we report that 1,25(OH)₂D₃-3-BE causes strong growth-inhibition in A498 and Caki 1 human kidney cancer cells with a significantly stronger efficacy than an equivalent concentration of 1,25(OH)₂D₃. In addition, we reveal that 1,25(OH)₂D₃-3-BE induces apoptosis in A498 cells, involving Akt-signaling pathway. Furthermore, we demonstrate that antiproliferative activity of 1,25(OH)₂D₃-3-BE is correlated with the activation of 1 α ,25-dihydroxyvitamin D₃-24-hydroxylase gene, qualitatively similar to 1,25(OH)₂D₃. This effect is obliterated by co-treatment with ZK 159222, an inhibitor of 1,25(OH)₂D₃-mediated gene expression. In summary, results described in this communication demonstrate that 1,25(OH)₂D₃-3-BE, a derivative of 1,25(OH)₂D₃ induces strong antiproliferative effect in kidney cancer cells via VDR-mediated signaling pathway. Therefore, 1,25(OH)₂D₃-3-BE has a strong translational potential as a therapeutic agent in renal cell carcinoma.

Introduction

Renal cell carcinoma (RCC) accounts for approximately 90-95% of all kidney cancer, which comprises approximately 3% of all adult malignancies with over 25,000 new cases and an estimated 8,000 deaths in the United States in 2006 (1). RCC has been increasing at a rate of approximately 3% a year in the United States and Europe and the overall death rate has not changed. Furthermore, approximately 50% of localized RCC develops into metastatic disease within a relatively short time frame (2). In addition, RCC is manifested by lack of early signs of neoplasm, and resistance to standard chemo- and radiation therapy (2, 3). Current therapeutic options include radical nephrectomy in early stages and immunotherapy in late and metastatic stages with some success. Anti-angiogenic and Raf-kinase inhibiting small molecules have also shown promise in treating RCC (4-6). Clearly, effective therapy for this deadly disease is urgently needed.

Numerous epidemiological studies have demonstrated the importance of dietary vitamin D in preventing various cancers (7-9). In addition, the therapeutic potential of $1\alpha,25$ -dihydroxyvitamin D₃ ($1,25(\text{OH})_2\text{D}_3$), the biologically active metabolite of vitamin D and its analogs in cancer is well-documented (10). However, inherent calcemic toxicity of this hormone, particularly at therapeutic doses, has prevented its general use as an anticancer agent. Thus, development of vitamin D analogs exhibiting potent antiproliferative activity and reduced systemic toxicity has become an active area of research.

For the past several years our laboratory has been engaged in developing novel analogs of $1,25(\text{OH})_2\text{D}_3$ and its pre-hormonal form, 25-hydroxyvitamin D₃ (25-OH-D₃) that covalently and specifically label the ligand-binding pocket of the nuclear receptor for $1,25(\text{OH})_2\text{D}_3$, the vitamin D receptor (VDR). Recently we reported that $1\alpha,25$ -dihydroxyvitamin D₃-3-bromoacetate ($1,25(\text{OH})_2\text{D}_3$ -3-BE) and 25-hydroxyvitamin D₃-3-bromoacetate (25-OH-D₃-3-BE), VDR-alkylating derivatives of $1,25(\text{OH})_2\text{D}_3$ and 25-OH-D₃ respectively, are more potent antiproliferative agents than $1,25(\text{OH})_2\text{D}_3$ in human cancer cell lines including hormone-sensitive and hormone-insensitive prostate cancer cell lines (11,12). Furthermore, we recently observed that $1,25(\text{OH})_2\text{D}_3$ -3-BE and 25-OH-D₃-3-BE significantly reduce tumor size in a mouse xenograft model of hormone insensitive prostate tumor (manuscripts in preparation).

In the present study we compared the growth-inhibitory property of $1,25(\text{OH})_2\text{D}_3$ -3-BE with $1,25(\text{OH})_2\text{D}_3$ in two renal cancer cells and examined the molecular mechanism of its cellular properties. Results of these studies and potential therapeutic application of $1,25(\text{OH})_2\text{D}_3$ -3-BE in renal cell carcinoma are presented.

Materials and Methods

Materials. $1,25(\text{OH})_2\text{D}_3$ -3-BE was synthesized according to our published procedure (13). A498 (HTB-44) and Caki 1 (HTB-46) cell lines were purchased from ATCC (Manassas, VA). ZK 159222 was obtained from Schering (Berlin, Germany).

Cellular Proliferation Assay. A498 and Caki 1 cells were grown in MEM and McCoy's 5A media respectively with 5% FBS according to manufacturer's specifications and plated into 96-well plates (500-1000 cells/well). The following day cells were treated with various doses of $1,25(\text{OH})_2\text{D}_3$ -3-BE or $1,25(\text{OH})_2\text{D}_3$ or ethanol (vehicle) (in media containing 5% FBS). The cells were dosed a total of three (3) times on alternate days. After seven (7) days, MTT solution (10 μl) was added to each well, and the plates were incubated at 37°C for 3 hours followed by the addition of detergent solution (100 μl /well). The plates were incubated at 25°C for 15 hr and then absorbance was read with a microplate reader.

Measurement of Apoptosis. Apoptosis measurements were carried out using the apoptosis kit (BD Biosciences) according to the manufacturer's instructions. Briefly, A498 kidney cancer cells were grown in DMEM media with 10% FBS to 60-70% confluence, and then were incubated (in media with 10% FBS) with 10^{-6}M of either $1,25(\text{OH})_2\text{D}_3$ or $1,25(\text{OH})_2\text{D}_3$ -3-BE for 6 hours in a cell incubator. The control cells contained equivalent amount of ethanol as vehicle control. The cells were harvested, washed with PBS and then once with binding buffer. Cells were re-suspended in 100 μl of 1X binding buffer and then stained with Annexin-FITC and Propidium Iodide (PI) for 15 minutes in the dark, followed by dilution with 1X binding buffer, according to the manufacturer instructions. Fluorescence was measured in a FACS analyzer with FITC in the X-axis and PI in the Y-axis in log scale.

Western analysis of phospho-Akt. A498 cells were plated at 3×10^5 cells/well in a six well dish. 16 hr later the cells were treated with $5 \times 10^{-7}\text{M}$ of $1,25(\text{OH})_2\text{D}_3$ -3-BE, $5 \times 10^{-7}\text{M}$ $1,25(\text{OH})_2\text{D}_3$ or ethanol control. 24 hrs later the cells were washed with PBS, scraped in PBS and centrifuged. Total cellular extracts were prepared by resuspending the cell pellets in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5) containing 50 mM NaF, 1 mM Na_3VO_4 and protease inhibitors (Protease Inhibitor Cocktail, Cat # P8340, Sigma-Aldrich, St. Louis, MO). After 10 min on ice, the extracts were cleared by micro-

centrifugation for 10 min, the supernatants transferred to new tubes and protein concentration of each extract determined by Bradford assay. Samples were separated on 4-12% MES NuPAGE gels (Invitrogen, Carlsbad, CA) and transferred to PVDF membrane. The blot was developed with mouse anti-phospho Akt (Ser 473, Cell Signaling, MA). The blot was stripped and re-probed for total Akt as a loading control with rabbit anti-Akt as a loading control (Cell Signaling, MA). Signals were detected by enhanced chemiluminescence (Perkin Elmer, Boston, MA) and autoradiography. In a parallel assay cells were grown and treated in full serum (10% FBS).

RT-PCR. A498 cells were plated at 3×10^5 cells per well of a six well dish. The following day, the cells were treated with various concentrations of $1,25(\text{OH})_2\text{D}_3$ or $1,25(\text{OH})_2\text{D}_3$ -3-BE. Sixteen (16) hours later, total RNA was prepared by Trizol extraction (Invitrogen, Carlsbad, CA). One microgram of total RNA was subjected to reverse transcription using moloney murine leukemia virus (MMLV) reverse transcriptase under standard conditions. Following cDNA synthesis, 1/10th of the reaction was subjected to PCR using gene specific primers to both 24-hydroxylase and beta-actin. The products were analyzed on a 1% agarose gel. In a separate experiment A498 cells were treated with 10^{-8}M of either $1,25(\text{OH})_2\text{D}_3$ -3-BE alone or in the presence of various concentrations of ZK 159222, an inhibitor of $1,25(\text{OH})_2\text{D}_3$ (14).

Results and Discussion

Numerous studies have registered strong promise of $1,25(\text{OH})_2\text{D}_3$ as a therapeutic agent for various cancers. However, its clinical use has been limited by the risk of toxicity related to hypercalcemia, hypercalciuria, and significant loss of body weight. Attempts to address the toxicity-issue have taken two approaches. In the first, combination of $1,25(\text{OH})_2\text{D}_3$ with standard chemotherapeutic agents are being investigated to harness synergy between these compounds. For example, Trump, Johnson and their coworkers have carried out several studies to demonstrate that toxic effects of $1,25(\text{OH})_2\text{D}_3$ can be mitigated by combination with dexamethasone or paclitaxel (15-19). The second approach involves the development of less toxic analogs of $1,25(\text{OH})_2\text{D}_3$ that maintain potent antiproliferative activity. These compounds are being developed as potential therapeutic agents. EB-1089, one such analog is currently in clinical trials for hepatocellular and pancreatic carcinomas (20, 21).

There is a serious paucity of information about the effect of $1,25(\text{OH})_2\text{D}_3$ and its analogs in renal cancer. In 1986 Nagakura *et al.* demonstrated that $1,25(\text{OH})_2\text{D}_3$ and some of its metabolites inhibited the growth of the renal cancer cell line KU-2 (22). In addition, Fuzioka *et al.* demonstrated that $1,25(\text{OH})_2\text{D}_3$ inhibited the growth of murine Renca renal cancer cell line-induced tumor in a mouse model (23). These results suggest potential utility of $1,25(\text{OH})_2\text{D}_3$ and its analogs in treating renal cancer.

Therapeutic potency of $1,25(\text{OH})_2\text{D}_3$ and its analogs depends on two factors, namely their ability to interact with VDR in target cells; and their bioavailability and pharmacokinetic properties. Interaction between $1,25(\text{OH})_2\text{D}_3$ and VDR is an equilibrium process. Therefore, in the steady state a finite amount of free $1,25(\text{OH})_2\text{D}_3$ (not bound to VDR) is always present in the equilibrium mixture, which undergoes rapid catabolic degradation (as shown in the cartoon in **Figure 1, Upper Panel**). From a therapeutic standpoint such catabolic degradation (of $1,25(\text{OH})_2\text{D}_3$) is met with high pharmacological doses that cause toxicity. In contrast, if catabolic degradation of $1,25(\text{OH})_2\text{D}_3$ is reduced/eliminated, its therapeutic potency can be enhanced significantly.

Chemical structures of $1,25(\text{OH})_2\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$ -3-BE are shown in **Figure 1**. $1,25(\text{OH})_2\text{D}_3$ -3-BE is a derivative of $1,25(\text{OH})_2\text{D}_3$ that contains a chemically reactive bromoacetate group which can react with a nucleophilic amino acid. Earlier we reported that $1,25(\text{OH})_2\text{D}_3$ -3-BE cross-links to the ligand-binding pocket of VDR by reacting with a single cysteine residue in the binding pocket (24). We argued that, $1,25(\text{OH})_2\text{D}_3$ -3-BE, once covalently linked to VDR, can not exit the binding pocket. Therefore, its interaction with VDR becomes an irreversible process. Furthermore, covalently linked $1,25(\text{OH})_2\text{D}_3$ -3-BE is prevented from

interacting with catabolic enzymes (as shown in the cartoon in **Figure 1, Bottom Panel**). We argued that such a process will increase the effective concentration of $1,25(\text{OH})_2\text{D}_3$ in tandem with $1,25(\text{OH})_2\text{D}_3$ -3-BE.

Another possible benefit of $1,25(\text{OH})_2\text{D}_3$ -3-BE is that it can potentially ‘titrate’ and engage all VDR molecules due to the kinetic nature of the alkylation process (**Figure 1, Bottom Panel**). It is an important consideration in cases where VDR level is low. For example, in a recent study Trydal *et al.* determined VDR level in 23 primary renal cell carcinomas and compared with autologous normal kidney tissue; and reported that mean value for the renal cell carcinomas is approximately three times less than autologous normal kidney tissue (25). Therefore, covalent labeling of VDR by $1,25(\text{OH})_2\text{D}_3$ -3-BE may compensate for lower VDR-copy number in some renal cancer cells, thereby enhancing the efficacy of this $1,25(\text{OH})_2\text{D}_3$ derivative.

$1,25(\text{OH})_2\text{D}_3$ -3-BE is more potent than $1,25(\text{OH})_2\text{D}_3$ in inhibiting the growth of renal carcinoma cells. To compare the antiproliferative potential of $1,25(\text{OH})_2\text{D}_3$ -3-BE versus $1,25(\text{OH})_2\text{D}_3$ we treated A498 and Caki 1 kidney cancer cells with various doses of $1,25(\text{OH})_2\text{D}_3$ -3-BE and $1,25(\text{OH})_2\text{D}_3$ and determined cell-viability. In A498 cells, treatment with 10^{-6}M $1,25(\text{OH})_2\text{D}_3$ -3-BE almost completely inhibited the growth of the cells, while an equivalent amount of $1,25(\text{OH})_2\text{D}_3$ inhibited the growth by approximately 10%. At 10^{-7}M and 10^{-8}M dose levels of $1,25(\text{OH})_2\text{D}_3$ -3-BE the antiproliferative effect is significantly stronger than an equivalent concentration of $1,25(\text{OH})_2\text{D}_3$ (**Figure 2a**). Caki 1 cells exhibited an increased sensitivity to $1,25(\text{OH})_2\text{D}_3$ -3-BE compared to A498 cells. In Caki 1 cells the growth inhibitory effect of $1,25(\text{OH})_2\text{D}_3$ -3-BE (10^{-6}M to 10^{-7}M) is more pronounced than in A498 cells. Additionally, equimolar doses of $1,25(\text{OH})_2\text{D}_3$ -3-BE and $1,25(\text{OH})_2\text{D}_3$ demonstrated that $1,25(\text{OH})_2\text{D}_3$ -3-BE is more efficacious than $1,25(\text{OH})_2\text{D}_3$ in eliciting inhibition of cell growth in Caki 1 cells (**Figure 2b**). These results suggest that irreversible linking of $1,25(\text{OH})_2\text{D}_3$ -3-BE into the hormone binding pocket of VDR in the target cells may be responsible for the enhanced antiproliferative activity of $1,25(\text{OH})_2\text{D}_3$ -3-BE versus $1,25(\text{OH})_2\text{D}_3$ in kidney cancer cells.

Further support for the above hypothesis stems from our observation in an earlier study with prostate cancer cells. DU-145 prostate cancer cells are resistant to $1,25(\text{OH})_2\text{D}_3$ -mediated growth inhibition due to high levels of CYP enzymes that catabolize the hormone (26,27). However, treatment of DU-145 cells with $1,25(\text{OH})_2\text{D}_3$ -3-BE resulted in strong growth inhibition suggesting unavailability of the compound inside the binding pocket to catabolizing enzymes (11).

$1,25(\text{OH})_2\text{D}_3$ -3-BE treatment induces apoptosis in A498 cells. The cellular mechanism(s) leading to growth inhibition by $1,25(\text{OH})_2\text{D}_3$ are complex. In most cases $1,25(\text{OH})_2\text{D}_3$ causes cells to arrest in the G_0/G_1 phase of the cell cycle (28). This effect is thought to be mediated by increased expression of the cyclin-dependent kinase (CDK) inhibitors p21 and p27, as well as other cell-cycle regulators (29). However, it has been reported that cellular growth inhibition mediated by $1,25(\text{OH})_2\text{D}_3$ correlates with increased apoptosis in some studies. For example, it is reported that $1,25(\text{OH})_2\text{D}_3$ induces apoptosis in LNCaP prostate cancer and MCF-7 breast cancer cells (30,31), but this result is not universal (32). Previously, we reported that $1,25(\text{OH})_2\text{D}_3$ -3-BE induces apoptosis in PC-3 prostate cancer cells (11). Therefore, to determine whether $1,25(\text{OH})_2\text{D}_3$ -3-BE inhibits A498 cell proliferation via apoptosis we measured apoptosis in A498 cells following $1,25(\text{OH})_2\text{D}_3$ -3-BE treatment by FACS analysis.

In this assay the bottom left quadrant (LL) indicates the percent amount of live cells, the bottom right (LR) quadrant indicates the percent of early apoptotic cells, the upper right (UR) quadrant indicates the percent of late apoptotic cells, and the upper left (UL) quadrant indicates dead cells (**Figure 3**). It should be noted that the upper left quadrant is not considered as a

measure of apoptotic death as it indicates total cell death contributed by apoptosis, necrosis or any other means.

Results from this experiment show that 10^{-6} M of $1,25(\text{OH})_2\text{D}_3$ causes approximately 26.85% of the cells to undergo early apoptosis (LR), while an equimolar amount of $1,25(\text{OH})_2\text{D}_3$ -3-BE causes 60.58% of the cells to undergo rapid apoptosis within 6 hours. These results are similar to our observation in PC-3 prostate cancer cells (11) and suggest $1,25(\text{OH})_2\text{D}_3$ -3-BE is more efficacious in promoting apoptosis than $1,25(\text{OH})_2\text{D}_3$.

$1,25(\text{OH})_2\text{D}_3$ -3-BE inhibits Akt phosphorylation in A498 cells. Akt (also known as protein kinase B, PKB) is a serine/threonine kinase which is activated by many signals in a phosphatidylinositol-3'-kinase (PI3K)-dependent manner. (33,34). Akt is involved in a variety of normal and tumorigenic functions such as cell proliferation, growth and survival. As a result Akt has been an attractive target for cancer drug discovery. Akt activation is common in many malignant cells, while expression of PTEN (phosphatase and tensin homolog deleted on chromosome 10), a negative regulator of Akt signaling, is down-regulated. For example, Hara *et al.* screened forty five (45) tumor samples from renal cell carcinoma (RCC) patients and reported that phosphorylated Akt (p-Akt) expression increased significantly in comparison with that of the corresponding normal kidney tissue (35). PTEN expression inversely correlated with the p-Akt expression. These alterations were specific for clear cell type RCC, but not for papillary or chromophobe type RCC. In addition, these researchers observed that an Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells which have high Akt activity.

As described earlier, $1,25(\text{OH})_2\text{D}_3$ -3-BE inhibits the growth of kidney cancer cells and induces apoptosis. To investigate the molecular mechanism of $1,25(\text{OH})_2\text{D}_3$ -3-BE-induced apoptosis in A498 cells, we examined the activation status of Akt, the pro-survival kinase. Akt is activated by phosphorylation at Thr308 and Ser473 which is known to promote cell survival and proliferation. Therefore, we analyzed the activation status of Akt by immunoblot analysis with an antibody specifically recognizing Ser473-phosphorylated Akt (pAkt) and an antibody recognizing total Akt (Akt) following overnight treatment of A498 cells with $1,25(\text{OH})_2\text{D}_3$ or $1,25(\text{OH})_2\text{D}_3$ -3-BE. Results of this assay are shown in **Figure 4**. $1,25(\text{OH})_2\text{D}_3$ -3-BE strongly reduced the level of pAkt. An equimolar concentration of $1,25(\text{OH})_2\text{D}_3$ also reduced Akt phosphorylation, but to a much lower degree than $1,25(\text{OH})_2\text{D}_3$ -3-BE. In summary, results of this study demonstrate that apoptotic behavior of $1,25(\text{OH})_2\text{D}_3$ -3-BE in kidney cancer cells may be mediated, at least partially, by signaling through the Akt pathway.

The cellular effects of $1,25(\text{OH})_2\text{D}_3$ -3-BE in kidney cancer cells are VDR-dependent. $1,25(\text{OH})_2\text{D}_3$ -3-BE is an alkylating agent and thus, in addition to alkylating VDR, it can potentially alkylate various cellular proteins non-specifically. The demonstration that cellular activities of $1,25(\text{OH})_2\text{D}_3$ -3-BE are mediated by VDR is an essential facet of our studies to evaluate the mechanisms of the cellular properties of this compound. Several genes, including osteocalcin, osteopontin and $1,25$ -dihydroxyvitamin D_3 -24-hydroxylase (CYP24) are known to be induced by $1,25(\text{OH})_2\text{D}_3$. In an earlier study we demonstrated that $1,25(\text{OH})_2\text{D}_3$ -3-BE induces mRNA for osteocalcin and CYP24 in human keratinocytes (36). In the current study we evaluated whether $1,25(\text{OH})_2\text{D}_3$ -3-BE is capable of modulating the expression of CYP24, similar to $1,25(\text{OH})_2\text{D}_3$, in A498 kidney cancer cells.

The results of this experiment, shown in **Figure 5**, demonstrate that treatment of A498 cells with 10^{-6} M to 10^{-9} M of $1,25(\text{OH})_2\text{D}_3$ strongly induces CYP24-message. In the case of $1,25(\text{OH})_2\text{D}_3$ -3-BE, induction of CYP24 mRNA is observed at 10^{-6} M to 10^{-8} M, but there is almost no detectable induction of CYP24 mRNA at 10^{-9} M. This is in contrast with the equivalent dose of $1,25(\text{OH})_2\text{D}_3$. These results demonstrate a log scale difference in inducing the message for CYP24 between $1,25(\text{OH})_2\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$ -3-BE. It is noteworthy that we observed a similar difference between 25-OH-D_3 -3-BE (the bromoacetate derivative of 25-OH-D_3) and $1,25(\text{OH})_2\text{D}_3$ in COS-7 cells transfected with a CYP24 reporter construct (12).

The CYP24 gene product catalyzes the introduction of a hydroxyl group at the 24-position in $1,25(\text{OH})_2\text{D}_3$, followed by multiple oxidations of the side chain leading to calcitroic acid, the final catabolite that is excreted (37). Therefore, CYP24 is the initiator of the catabolic degradation of $1,25(\text{OH})_2\text{D}_3$. We hypothesize that covalent attachment of $1,25(\text{OH})_2\text{D}_3$ -3-BE into the ligand binding pocket of VDR will decrease its catabolism. In essence it would require more $1,25(\text{OH})_2\text{D}_3$ -3-BE to induce the same level of CYP24 message as $1,25(\text{OH})_2\text{D}_3$. Therefore, one log scale difference between concentrations of $1,25(\text{OH})_2\text{D}_3$ -3-BE and $1,25(\text{OH})_2\text{D}_3$ to induce same level of CYP24-message is expected; and this is reflected in the results shown in **Figure 5**.

To further investigate the requirement for VDR in $1,25(\text{OH})_2\text{D}_3$ -3-BE action, we used the specific VDR antagonist, ZK159222 which has been shown to be effective in blocking VDR-mediated gene regulation (14). A498 cells were treated with either $1,25(\text{OH})_2\text{D}_3$ -3-BE or ZK 15922 alone or in combination, and the levels of CYP24 mRNA analyzed by RT-PCR. We observed a strong inhibition of CYP24 induction when ZK 159222 is co-administered with $1,25(\text{OH})_2\text{D}_3$ -3-BE in a 1:1 molar ratio demonstrating that $1,25(\text{OH})_2\text{D}_3$ -3-BE binds to and activates VDR. In an earlier study we demonstrated that ^{14}C - $1,25(\text{OH})_2\text{D}_3$ -3-BE specifically labeled VDR in extracts of ROS 17/2.8 bone cells and calf thymus nuclear cytosol, indicating that labeling by $1,25(\text{OH})_2\text{D}_3$ -3-BE is VDR-specific (38). Therefore, collectively these results strongly suggest that the cellular effects of $1,25(\text{OH})_2\text{D}_3$ -3-BE are related to specific affinity alkylation of VDR by $1,25(\text{OH})_2\text{D}_3$ -3-BE.

Protein and DNA alkylating compounds such as estramustine, lomustine, procarazine, busulfan, cyclophosphamide, chlorambucil, temozolomide, platinum coordination complexes etc. are important components in the standard cancer chemotherapeutic regimen. But the majority of these compounds are non target-specific and, produce significant side effects, particularly at pharmacological doses. On the other hand, affinity alkylating compounds such as $1,25(\text{OH})_2\text{D}_3$ -3-BE targets and covalently labels the hormone-binding site of VDR. Thus, this compound is expected to possess greater antiproliferative activity than $1,25(\text{OH})_2\text{D}_3$ in cancer cells.

One concern regarding potential therapeutic use of $1,25(\text{OH})_2\text{D}_3$ -3-BE is its hydrolytic potential. Since it contains an ester bond, hydrolysis would produce $1,25(\text{OH})_2\text{D}_3$ and bromoacetic acid. It could be argued that the growth-inhibitory property of $1,25(\text{OH})_2\text{D}_3$ -3-BE is due to $1,25(\text{OH})_2\text{D}_3$ and/or bromoacetic acid, or a combination of the two. In an earlier study we demonstrated that antiproliferative property of $1,25(\text{OH})_2\text{D}_3$ -3-BE is due solely to its unhydrolyzed and intact form, and equivalent amounts of $1,25(\text{OH})_2\text{D}_3$ and bromoacetic acid have no effect on cellular growth (11). Therefore, we conclude that, even if $1,25(\text{OH})_2\text{D}_3$ -3-BE undergoes partial hydrolysis in a living system, the unhydrolyzed and intact form of $1,25(\text{OH})_2\text{D}_3$ -3-BE represents the biologically active form. It is also noteworthy that, while $1,25(\text{OH})_2\text{D}_3$ -3-BE produced strong antiproliferative and apoptotic effects, equivalent amounts of $1,25(\text{OH})_2\text{D}_3$ failed to produce such effects. Therefore even if 'some' amount of $1,25(\text{OH})_2\text{D}_3$ is produced by the hydrolysis of $1,25(\text{OH})_2\text{D}_3$ -3-BE, it should have minimal effect. Drugs containing hydrolysable bonds are fairly common. For example aspirin contains a hydrolysable ester bond, yet acetyl salicylate is the active principle of this drug, and not salicylic acid, its hydrolyzed form. In the case of $1,25(\text{OH})_2\text{D}_3$ -3-BE, both this molecule and its hydrolyzed product ($1,25(\text{OH})_2\text{D}_3$) are biologically active, but $1,25(\text{OH})_2\text{D}_3$ -3-BE is a significantly stronger antiproliferative-apoptotic agent in rena carcinoma cells than $1,25(\text{OH})_2\text{D}_3$, as delineated in this report.

During the past decade hundreds of vitamin D-analogs have been synthesized with the goal of obtaining a better antitumor/toxicity ratio and tumor-specific effects. Although a few of these analogs have successfully completed pre-clinical studies for several cancers, and at least one analog has shown strong effects in phase II trials for pancreatic and hepatocellular carcinomas (20, 21), the majority of these compounds have been proven to be of limited

therapeutic value due to toxicity. As a result new strategies for developing such analogs are required. As detailed in this communication we have developed 1,25(OH)₂D₃-3-BE, based on our knowledge about the interaction between 1,25(OH)₂D₃ and VDR-mediated cell-signaling processes. We have demonstrated that this compound possesses strong antiproliferative and apoptotic properties in kidney cancer cells. Therefore, 1,25(OH)₂D₃-3-BE has a strong translational potential as a therapeutic agent for kidney cancer.

Acknowledgement

The authors acknowledge the following grant support for this work: Department of Defense Grant PC 051136 and Community Technology Fund, Boston University (RR), American Cancer Society Research Scholar Grant RSG-04-170-01-CNE (JRL), Department of Defense contract grant DAMD 17-03-1-0213 and National Cancer Institute CA 101992 (DVF).

Figure Legends

Figure 1: Cartoon depicting the interaction of VDR with 1,25(OH)₂D₃ and 1,25(OH)₂D₃-3-BE, and possible impact on such interaction on transcription and catabolism.

Figure 2: Cell-viability assay of A-498 (**Figure 2a**) and Caki-1 cells (**Figure 2b**). Briefly, A498 and Caki 1 cells were grown in manufacturer recommended media with FBS in 96-well plates (500-1000 cells/well) followed by treatment with various doses of 1,25(OH)₂D₃-3-BE or 1,25(OH)₂D₃ or ethanol (vehicle) (in media containing 5% FBS). The cells were dosed a total of three (3) times on alternate days. After seven (7) days, MTT solution (10 µl) was added to each well, and the plates were incubated at 37°C for 3 hours followed by the addition of detergent solution (100 µl/well). The plates were incubated at 25°C for 15 hr and then absorbance was read with a microplate reader. Absorbance from treated cells are plotted as percent of ethanol-control. There were eight replicates for each dose and control.

Figure 3: Annexin-PI-staining-FACS analysis of A-498 cells treated with 1,25(OH)₂D₃ or 1,25(OH)₂D₃-3-BE. Briefly, A498 cells were grown to 60-70% confluence, and then were incubated (in media with 10% FBS) with 10⁻⁶M of either 1,25(OH)₂D₃ or 1,25(OH)₂D₃-3-BE for 6 hours in a cell incubator. The control cells contained equivalent amount of ethanol as vehicle control. The cells were harvested, washed with PBS and then once with binding buffer. Cells were re-suspended in 100 µl of 1X binding buffer and then stained with Annexin-FITC and Propidium Iodide (PI) for 15 minutes in the dark, followed by dilution with 1X binding buffer. Fluorescence was measured in a FACS analyzer with FITC in the X-axis and PI in the Y-axis in log scale.

Figure 4: Effects of 1,25(OH)₂D₃ and 1,25(OH)₂D₃-BE on phosphorylation of Akt in A498 cells. A498 cells were incubated with 5 × 10⁻⁷M of 1,25(OH)₂D₃ and 1,25(OH)₂D₃-BE or ethanol control for 24 hours and immunoblot analysis was used to assess the levels of phosphorylated Akt (p-Akt). The blot was stripped and re-probed for total Akt as a loading control. The results are representative of two independent experiments.

Figure 5: Comparison of dose dependent increase of Cyp 24 mRNA by 1,25(OH)₂D₃ and 1,25(OH)₂D₃-BE in A498 cells. A498 cells were treated with ethanol control or the indicated doses of 1,25(OH)₂D₃ and 1,25(OH)₂D₃-BE for 24 hours, total RNA prepared and Cyp 24 mRNA levels assessed by RT-PCR. Beta actin mRNA levels were determined for each sample as control.

Figure 6: Induction of Cyp 24 mRNA by 1,25(OH)₂D₃-BE is blocked by a vitamin D receptor antagonist. A498 cells were treated with ethanol control, 1,25(OH)₂D₃-BE (10⁻⁸M) or a combination of 1,25(OH)₂D₃-3-BE (10⁻⁸M) and increasing amounts of ZK 159222 for 24 hours. (A) RT-PCR analysis was performed to assess Cyp 24 mRNA levels. Beta actin mRNA levels were determined for each sample as control. (B) Graphical representation of the band intensities in (A). Values represent the Cyp 24 band intensity normalized to the corresponding beta actin band intensity for each sample.

REFERENCES

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics 2006. *CA Cancer J Clin* 2006;56(2):106-130.
2. van Spronsen DJ, Mulders PFA, De Mulder PHM. Novel treatments for metastatic renal cell carcinoma. *Crit Rev Oncol./Hemat* 2005;55: 177-191.
3. Lam JS, Leppert JT, Figlin RA, Belldegren AS. Role of molecular markers in diagnosis and therapy of renal cell carcinoma. *Urology* 2005;66 Suppl 5A:1-9.
4. Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. *Can J Urol* 2005;12 Suppl 1:66-70.
5. Ko YJ, Atkins MB. Chemotherapies and immunotherapies for metastatic kidney cancer. *Curr Urol Rep* 2005; 6:35-42.
6. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal carcinoma. *J Clin Oncol* 2005;23:1028-1043.
7. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *J Natl Cancer Inst* 2006; 98:451-459.
8. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:203-210.
9. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst* 2005;97:1688-1694.
10. Matsuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. *Mol Cancer Thera* 2006;5:797-808.
11. Swamy N, Persons K, Chen TC, Ray R. 1alpha,25-Dihydroxyvitamin D₃-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D₃ displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. *J Cellular Biochem* 2003;89:909-916.
12. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel N, Mehta RG, Holick MF, Ray R. Inhibition of proliferation and induction of apoptosis by 25-

hydroxyvitamin D₃-3 β -(2)-bromoacetate, a non-toxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D₃ in prostate cancer cells. Clin Cancer Res 2004;10:8018-8027.

13. Ray R, Ray S, Holick MF. 1 α ,25-dihydroxyvitamin D₃-3-deoxy-3-bromoacetate, an affinity labeling analog of 1 α ,25-dihydroxyvitamin D₃. Bioorg Chem 1994;22: 276-283.

14. Toell A, Gonzalez MM, Ruf D, Steinmeyer A, Ishizuka S, Carlberg C. Different molecular mechanisms of vitamin D(3) receptor antagonists. Mol Pharmacol 2001;59:1478-1485.

15. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-3764.

16. Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS. Enhancement of 1,25-dihydroxyvitamin D₃-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998;90:134-141.

17. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5:1339-1345.

18. Hershberger, PA, Yu, WD, Modzelewski, RA, Rueger, RM, Johnson, CS, Trump, DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity *in vitro* and *in vivo* and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-1051.

19. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol phase I trial of calcitriol and paclitaxel. Clin Pharma Ther 2003;72:648-659.

20. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, BachHansen J, Steward WP, Skov T, Burcharth F, Evans TR. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89:252-257.

21. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680-685.

22. Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H. Inhibitory effect of 1- α ,25-dihydroxyvitamin D₃ on the growth of the renal carcinoma cell line. Kidney Intl 1986;29:834-840.

23. Fuzioka T, Hasegawa M, Ishikura K, Matsuhita Y, Sato M, Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D₃ agents in murine renal cell carcinoma. J Urol 1996;160:247-51.

24. Swamy N, Xu W, Paz N, Hsieh J-C, Haussler MR, Maalouf GJ, Mohr SC, Ray R. Molecular modeling, affinity labeling and site-directed mutagenesis define the key points of

interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1,25-dihydroxyvitamin D₃. *Biochemistry* 2000;39:12162-12171.

25. Trydal T, Bakke A, Aksnes L, Aarskog D. 1,25-Dihydroxyvitamin D₃ receptor measurement in primary renal cell carcinomas and autologous normal kidney tissue. *Cancer Res* 1998;48:2458-2461.
26. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D₃ analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D₃. *Endocrinology* 1995;136:20-26.
27. Ly H, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1- α ,25-dihydroxyvitamin D₃ to inhibit growth of DU-145 human prostate cancer cells by blocking 24-hydroxylase activity. *Endocrinology* 1999;140:2071-2076.
28. Pols HAP, Birkenhager JC, Foekenes JPTNM. Vitamin D: a modulator of cell proliferation and differentiation. *J Steroid Biochem Mol Biol* 1990;37:873-876.
29. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman L. Transcriptional activation of the CDK inhibitor p21 by vitamin D₃ leads to the induced differentiation of the myelomonocytic cell line U937. *Genes Dev* 1996;10:142-153.
30. Blatt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. *Endocrinology* 2000;141:10-17.
31. Simbolli-Campbell M, Narvaez CJ, Tenniswood J, Welsh J. 1,25-Dihydroxyvitamin D₃ induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. *J Steroid Biochem* 1996;58:367-376.
32. Zhuang S-H, Burnstein KL. Antiproliferative effect of 1 α ,25-dihydroxyvitamin D₃ in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. *Endocrinology* 1998;139:1197-1207.
33. Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. *Expert Opin Investig Drugs* 2004;13:787-797.
34. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. *Anticancer Drugs* 2005;16:797-803.
35. Hara S, Oya M, Mizuno R, Horiuchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. *Ann Oncol* 2005;16:928-933.
36. Chen ML, Ray S, Swamy N, Holick MF, Ray R. Mechanistic studies to evaluate the enhanced anti-proliferation of human keratinocytes by 1 α ,25-dihydroxyvitamin D₃-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1 α ,25-dihydroxyvitamin D₃. *Arch Biochem Biophys* 1999;370:34-44.
37. Makin G, Lohnes D, Byford V, Ray R, Jones G. Target cell metabolism of 1,25-dihydroxyvitamin D₃ to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. *Biochem J* 1989;262:173-180.

38. Ray R, Swamy N, MacDonald PN, Ray S, Haussler MR, Holick MF. Affinity labeling of 1,25-dihydroxyvitamin D₃ receptor. J Biol Chem 1996;271:2012-2017.





Figure 1

Figures 2a and 2b








Figure 3

(BEST AVAILABLE COPY)




Figure 4




Figure 5




Figure 6